Research Analysts Issue Forecasts for ACRV Q1 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Acrivon Therapeutics in a research report issued to clients and investors on Thursday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.53) per share for the quarter, up from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($1.11) EPS, FY2029 earnings at ($0.84) EPS and FY2030 earnings at $0.04 EPS.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.49).

Several other equities research analysts also recently issued reports on ACRV. Jefferies Financial Group reiterated a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a report on Monday, December 29th. Piper Sandler increased their price objective on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Finally, Wall Street Zen downgraded shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 1st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Acrivon Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Acrivon Therapeutics Price Performance

Shares of ACRV stock opened at $1.60 on Monday. Acrivon Therapeutics has a 1-year low of $1.05 and a 1-year high of $5.65. The firm’s 50-day simple moving average is $1.71 and its 200-day simple moving average is $1.95. The firm has a market cap of $61.98 million, a P/E ratio of -0.79 and a beta of 1.79.

Institutional Trading of Acrivon Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Schonfeld Strategic Advisors LLC acquired a new stake in Acrivon Therapeutics in the fourth quarter worth approximately $40,000. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Acrivon Therapeutics during the 4th quarter valued at $44,000. Focus Partners Wealth acquired a new position in shares of Acrivon Therapeutics during the 3rd quarter valued at $36,000. Quadrature Capital Ltd bought a new stake in shares of Acrivon Therapeutics in the 4th quarter worth $50,000. Finally, Invesco Ltd. bought a new stake in shares of Acrivon Therapeutics in the 1st quarter worth $72,000. Institutional investors own 71.62% of the company’s stock.

Insider Transactions at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen acquired 49,000 shares of Acrivon Therapeutics stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average price of $1.68 per share, for a total transaction of $82,320.00. Following the transaction, the chief executive officer directly owned 2,095,771 shares of the company’s stock, valued at $3,520,895.28. This trade represents a 2.39% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders purchased 67,832 shares of company stock worth $114,534. Insiders own 8.50% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.